{"classes":[{"categories":[{"measurements":[{"comment":"95% confidence interval, 5.6 to not reached","groupId":"OG000","lowerLimit":"5.6","upperLimit":"NA","value":"13.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Computed using the Kaplan-Meier method. Ninety-five percent confidence intervals will be constructed and selected results will be illustrated using figures and plots.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nbelinostat: Given IV","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Duration of time from start of treatment to time of progression, assessed up to 5 years","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}